Clinical Trial

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

Study acronym: BEACON
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-07-11; most recent amendment 2025-12-15.
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Status change: Not Yet Recruiting → Recruiting 2022-09-30
Trial Details
NCT Number NCT05456880
Lead Sponsor Beam Therapeutics Inc.
Conditions Sickle Cell Disease
Enrollment 15 participants
Start Date 2022-08-30
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2025-12-16